ARCHIVES

NCI Seen Shifting Away From Comprehensive Center Emphasis Toward Encouraging Clinical Excellence

This article is from The Cancer Letter archive.

Vol. 02 No. 18 | April 30, 1976

Download PDF Visit The Full Archive

Related Articles

FDA’s Young Still Not Satisfied With Distribution Plan

September 9, 1977

FDA Approves Genetic Test For Breast Cancer Patients

January 25, 2008

Erbitux Addition to Chemotherapy Regimen Can Make Inoperable Disease Operable

April 26, 2013

FDA Oncology Unit Fastest in Approvals Despite Having Highest Workload

May 9, 2014

NCI Staff Recommends Moving Cooperative Groups Into DCT, Increase Funding, Switch Emphasis

July 4, 1975

FDA Advisors Unanimously Turn Down GPC Biotech’s Orplatna for Prostate Cancer.

July 27, 2007